Featured Research

from universities, journals, and other organizations

Potent And Selective Anti-tumor Agent Found For Human Gastric Adenocarcinoma

Date:
April 20, 2009
Source:
World Journal of Gastroenterology
Summary:
A research group in China demonstrated that acetylshikonin had significant anti-tumor effects on SGC-7901 cells both in vitro and in vivo. The effect of acetylshikonin on SGC-7901 cells is related to induction of the cell apoptosis. It suggests that acetylshikonin has good perspectives as a potent and selective anti-tumor agent on human gastric adenocarcinoma although further studies are clearly needed to prove the possibility.

Previous studies on shikonin, a chemical derived from the Chinese medicinal herb had anti-tumor effects although it was found to be toxic. However, an acetyl derivative, acetylshikonin had less toxicity and prevented the growth of sarcomas. However, knowledge of the effect of acetylshikonin on gastric cancer in vitro and especially in vivo is unknown.

A research team led by Prof. Zhou from Department of Pharmacology of Sichuan University analyzes the effect of acetylshikonin on gastric cancer cell line SGC-7901 and in vivo in nude mice injected with the same cells.

The authors used the gastric carcinoma cell line SGC-7901 and treated the cells in culture with various doses of acetylshikonin. They observed that increased doses of the drug resulted in increased death of the cells using MTT assay. Further analysis using TUNEL assay, Hoechst staining and FACScan showed that cell death is mediated by apoptotic pathways. This was further by increase in the Bax and decrease in Bcl-2 both at the mRNA and protein level as shown by RT-PCR and western blot analysis. In order to see if the drug was also effective in vivo, the authors injected the cells subcutaneously into nude mice and challenged them with acetylshikonin along with cyclophosphamide as a positive control.

Consistent with their in vitro studies, administration of acetylshikonin into mice resulted in significant shrinkage of tumor volume and also showed increased ratio of Bax/Blc-2 as seen with cultured cells. Taken together, these data suggest that acetylshikonin has potent anti-tumor activity against gastric tumors and should be explored for further development for therapeutic use.


Story Source:

The above story is based on materials provided by World Journal of Gastroenterology. Note: Materials may be edited for content and length.


Journal Reference:

  1. Zeng Y, Liu G, Zhou LM. Inhibitory effect of acetylshikonin on human gastric carcinoma cell line SGC-7901 in vitro and in vivo. World J Gastroenterol, 2009; 15(15): 1816-1820 [link]

Cite This Page:

World Journal of Gastroenterology. "Potent And Selective Anti-tumor Agent Found For Human Gastric Adenocarcinoma." ScienceDaily. ScienceDaily, 20 April 2009. <www.sciencedaily.com/releases/2009/04/090420103742.htm>.
World Journal of Gastroenterology. (2009, April 20). Potent And Selective Anti-tumor Agent Found For Human Gastric Adenocarcinoma. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2009/04/090420103742.htm
World Journal of Gastroenterology. "Potent And Selective Anti-tumor Agent Found For Human Gastric Adenocarcinoma." ScienceDaily. www.sciencedaily.com/releases/2009/04/090420103742.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com
$23.6 Billion Awarded To Widow In Smoking Lawsuit

$23.6 Billion Awarded To Widow In Smoking Lawsuit

Newsy (July 20, 2014) Cynthia Robinson claims R.J. Reynolds Tobacco Company hid the health and addiction risks of its products, leading to the death of her husband in 1996. Video provided by Newsy
Powered by NewsLook.com
Tooth Plaque Provides Insight Into Diets Of Ancient People

Tooth Plaque Provides Insight Into Diets Of Ancient People

Newsy (July 19, 2014) Research on plaque from ancient teeth shows that our prehistoric ancestor's had a detailed understanding of plants long before developing agriculture. Video provided by Newsy
Powered by NewsLook.com
Contaminated Water Kills 3 Babies in South African Town

Contaminated Water Kills 3 Babies in South African Town

AFP (July 18, 2014) Contaminated water in South Africa's northwestern town of Bloemhof kills three babies and hospitalises over 500 people. The incident highlights growing fears over water safety in South Africa. Duration: 02:22 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins